株探米国株
英語
エドガーで原本を確認する
6-K 1 ea0200177-6k_sapiens.htm REPORT OF FOREIGN PRIVATE ISSUER

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of February 2024

 

Commission File Number 000-20181

 

SAPIENS INTERNATIONAL CORPORATION N.V.

(Translation of Registrants name into English)

 

Azrieli Center

26 Harokmim St.

Holon, 5885800 Israel

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒      Form 40-F ☐

 

 

 

 

 

 

CONTENTS

 

Exhibit No.   Title of Exhibit
99.1   Press Release

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Sapiens International Corporation N.V.
   
Date: February 20, 2024 By: /s/ Roni Giladi
    Name:  Roni Giladi
    Title: Chief Financial Officer

 

2

 

 

Exhibit Index

 

The following exhibit is furnished as part of this Form 6-K:

 

Exhibit   Description
99.1   Press Release

 

 

3

 
EX-99.1 2 ea0200177ex99-1_sapiens.htm PRESS RELEASE

Exhibit 99.1

 

 

Sapiens Reports Fourth Quarter 2023 Financial Results

 

February 20, 2024 – Sapiens International Corporation, (NASDAQ and TASE: SPNS), a leading global provider of software solutions for the insurance industry, today announced its financial results for the fourth quarter ended December 31, 2023.

 

Summary Results for Fourth Quarter 2023 (USD in millions, except per share data)

 

    GAAP             Non-GAAP        
    Q4 2023     Q4 2022     % Change       Q4 2023     Q4 2022     % Change  
Revenue   $ 130.9     $ 119.5       9.5 %     $ 130.9     $ 119.5       9.6 %
Gross Profit   $ 55.9     $ 50.3       11.2 %     $ 59.4     $ 53.8       10.4 %
Gross Margin     42.8 %     42.1 %     70 bps         45.4 %     45.0 %     40 bps  
Operating Income   $ 20.1     $ 16.5       21.9 %     $ 24.2     $ 21.1       14.7 %
Operating Margin     15.4 %     13.8 %     160 bps         18.4 %     17.6 %     80 bps  
Net Income (*)   $ 17.0     $ 13.4       27.0 %     $ 20.1     $ 18.0       11.4 %
Diluted EPS   $ 0.30     $ 0.24       25.0 %     $ 0.36     $ 0.32       12.5 %

 

Summary Results for Full Year end 2023 (USD in millions, except per share data)

 

    GAAP           Non-GAAP      
    2023     2022     % Change       2023     2022     % Change  
Revenue   $ 514.6     $ 474.7       8.4 %     $ 514.8     $ 474.8       8.4 %
Gross Profit   $ 219.6     $ 200.2       9.7 %     $ 233.0     $ 213.5       9.1 %
Gross Margin     42.7 %     42.2 %     50 bps         45.3 %     45.0 %     30 bps  
Operating Income   $ 78.9     $ 66.5       18.6 %     $ 94.1     $ 83.5       12.8 %
Operating Margin     15.3 %     14.0 %     130 bps         18.3 %     17.6 %     70 bps  
Net income (*)   $ 62.4     $ 52.6       18.7 %     $ 75.0     $ 67.2       11.7 %
Diluted EPS   $ 1.12     $ 0.95       17.9 %     $ 1.35     $ 1.21       11.6 %

 

(*) Attributable to Sapiens’ shareholders

 

1


 

Roni Al-Dor, President and CEO of Sapiens, stated, “In 2023, Sapiens executed its growth strategy across our regions and product lines, achieving an 8.4% growth in non-GAAP revenue and bolstering non-GAAP operating profit by an impressive 12.8%. Our ARR in the fourth quarter was $164.8 million, a growth of 13.5% compared to the fourth quarter of 2022.

 

Our North American and European businesses have shown robust growth, and we are well-positioned to sustain growth in these markets in 2024. We completed multiple successful go-lives globally and demonstrated noteworthy expansion of our market share by signing about 30 new deals with both new and existing customers across core, Data, digital, and cloud in P&C, Workers’ Comp, Life, and Reinsurance. Furthermore, we anticipate continued momentum and growth with new logos and cross-selling opportunities within our existing accounts across all regions throughout 2024.”

 

“Key initiatives that will guide our strategic direction in 2024 include our continued transition to SaaS with all our products, with our evolved Sapiens Insurance Platform, an end-to-end integrated business-led SaaS platform with advanced technology and data capabilities,” continued Mr. Al-Dor. “In North America, EMEA, and APAC, we are increasing our headcount across sales, marketing, and product marketing to drive success. We remain focused on further expansion in North America, leveraging our investments in the region, and increasing our market share in Europe where we have a strong footprint.”

 

“We are introducing 2024 guidance for non-GAAP revenue in a range of $550 million to $555 million, and non-GAAP operating margin in a range of 18.1% to 18.5%,” concluded Mr. Al-Dor.

 

Quarterly Results Conference Call

 

Management will host a conference call and webcast on February 20, 2024, at 9:30 a.m. Eastern Time (4:30 p.m. in Israel) to review and discuss Sapiens’ results. Please call the following numbers (at least 10 minutes before the scheduled time) to participate:

 

North America (toll-free): 1-888-642-5032

 

International: 972-3-9180609

 

UK: 0-800-917-5108

 

The live webcast of the call can be viewed on Sapiens’ website at: https://www.sapiens.com/investor-relations/ir-events-presentations. A replay of the call will be available one business day following the completion of the event, at the same link for 90 days.

 

2


 

Non-GAAP Financial Measures

 

This press release contains the following non-GAAP financial measures: non-GAAP revenue, ARR, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income attributed to Sapiens shareholders, non-GAAP basic and diluted earnings per share, Adjusted EBITDA and Adjusted Free Cash-Flow.

 

Sapiens believes that these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to Sapiens’ financial condition and results of operations. The Company’s management uses these non-GAAP measures to compare the Company’s performance to that of prior periods for trend analyses, for purposes of determining executive and senior management incentive compensation and for budgeting and planning purposes. These measures are used in financial reports prepared for management and in quarterly financial reports presented to the Company’s board of directors. The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends, and in comparing the Company’s financial measures with other software companies, many of which present similar non-GAAP financial measures to investors.

 

Non-GAAP financial measures consist of GAAP financial measures adjusted to exclude: Valuation adjustment on acquired deferred revenue, amortization of capitalized software development and other intangible assets, capitalization of software development, stock-based compensation, compensation related to acquisition and acquisition-related costs, restructuring and cost reduction costs, and tax adjustments related to non-GAAP adjustments.

 

Management of the Company does not consider these non-GAAP measures in isolation, or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements. In addition, they are subject to inherent limitations, as they reflect the exercise of judgment by management about which expenses and income are excluded or included in determining these non-GAAP financial measures.

 

To compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. Sapiens urges investors to review the reconciliation of its non-GAAP financial measures to the comparable GAAP financial measures, which it includes in press releases announcing quarterly financial results, including this press release, and not to rely on any single financial measure to evaluate the Company’s business.

 

3


 

Reconciliation tables of the most comparable GAAP financial measures to the non-GAAP financial measures used in this press release are included with the financial tables of this release.

 

The Company defines Annual Recurring Revenue (“ARR”) as the annualized value of our revenue from customer subscriptions, term licenses, maintenance, application maintenance, and cloud solutions. The ARR run rate is equal to the product of (i) the sum of these revenues in our most recently completed fiscal quarter, multiplied by (ii) four.

 

The Company defines Adjusted EBITDA as net profit, adjusted to eliminate valuation adjustment on acquired deferred revenue, stock-based compensation expense, depreciation and amortization, capitalization of software development costs, compensation expenses related to acquisition and acquisition-related costs, restructuring and cost reduction costs, financial expense (income), provision for income taxes and other income (expenses). These amounts are often excluded by other companies as well, in order to help investors understand the operational performance of their business.

 

The Company uses Adjusted EBITDA as a measurement of its operating performance, because it assists in comparing the operating performance on a consistent basis by removing the impact of certain non-cash and non-operating items. Adjusted EBITDA reflects an additional way of viewing aspects of the operations that the Company believes, when viewed with the GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provide a more complete understanding of factors and trends affecting its business. The Company uses Adjusted Free Cash-Flow as a measurement of its operating performance, and reconciles cash-flow from operating activities to Adjusted Free Cash-Flow, while reducing the amounts for capitalization of software development costs and capital expenditures. The Company adds back cash payments made for former acquisitions in respect of future performance targets and retention criteria as determined upon acquisition date of the respective acquired company, which were included in the cash-flow from operating activities. We believe that Adjusted Free Cash-Flow is useful in evaluating our business, because Adjusted Free Cash-Flow reflects the cash surplus available to fund the expansion of our business.

 

4


 

About Sapiens

 

Sapiens International Corporation (NASDAQ and TASE: SPNS) empowers the financial sector, with a focus on insurance, to transform and become digital, innovative and agile. Backed by more than 40 years of industry expertise, Sapiens offers a complete insurance platform, with pre-integrated, low-code solutions and a cloud-first approach that accelerates customers’ digital transformation. Serving over 600 customers in 30 countries, Sapiens offers insurers across property and casualty, workers compensation and life markets the most comprehensive set of solutions, from core to complementary, including Reinsurance, Financial & Compliance, Data & Analytics, Digital, and Decision Management.  For more information visit www.sapiens.com or follow us on LinkedIn.

 

Investor and Media Contact

 

Yaffa Cohen-Ifrah
Chief Marketing Officer and Head of
Investor Relations, Sapiens
Yaffa.cohen-ifrah@sapiens.com
+1 917-533-4782  

Investors Contact Kimberly Rogers

 

Managing Director, Hayden IR
+1 541-904-5075
kim@HaydenIR.com

 

5


 

Forward Looking Statements

 

Certain matters discussed in this press release that are incorporated herein by reference are forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our beliefs, assumptions and expectations, as well as information currently available to us. Such forward-looking statements may be identified by the use of the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “will,” “plan” and similar expressions. Such statements reflect our current views with respect to future events and are subject to certain risks and uncertainties. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: the degree of our success in our plans to leverage our global footprint to grow our sales; the degree of our success in integrating the companies that we have acquired through the implementation of our M&A growth strategy; the lengthy development cycles for our solutions, which may frustrate our ability to realize revenues and/or profits from our potential new solutions; our lengthy and complex sales cycles, which do not always result in the realization of revenues; the degree of our success in retaining our existing customers or competing effectively for greater market share; difficulties in successfully planning and managing changes in the size of our operations; the frequency of the long-term, large, complex projects that we perform that involve complex estimates of project costs and profit margins, which sometimes change mid-stream; the challenges and potential liability that heightened privacy laws and regulations pose to our business; occasional disputes with clients, which may adversely impact our results of operations and our reputation; various intellectual property issues related to our business; potential unanticipated product vulnerabilities or cybersecurity breaches of our or our customers’ systems; risks related to the insurance industry in which our clients operate; risks associated with our global sales and operations, such as changes in regulatory requirements, wide-spread viruses and epidemics like the recent novel coronavirus pandemic, which adversely affected our results of operations, or fluctuations in currency exchange rates; and risks related to our principal location in Israel and our status as a Cayman Islands company. While we believe such forward-looking statements are based on reasonable assumptions, should one or more of the underlying assumptions prove incorrect, or these risks or uncertainties materialize, our actual results may differ materially from those expressed or implied by the forward-looking statements. Please read the risks discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F, in order to review conditions that we believe could cause actual results to differ materially from those contemplated by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, to conform these statements to actual results or to changes in our expectations.

 

6


  

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENT OF INCOME

U.S. dollars in thousands (except per share amounts)

 

    Three months ended     Year ended  
    December 31,     December 31,  
    2023     2022     2023     2022  
    (unaudited)     (unaudited)     (unaudited)     (unaudited)  
                         
Revenue     130,859       119,463       514,584       474,736  
Cost of revenue     74,910       69,158       294,990       274,573  
                                 
Gross profit     55,949       50,305       219,594       200,163  
                                 
Operating expenses:                                
Research and development, net     16,084       15,251       63,475       58,656  
Selling, marketing, general and administrative     19,776       18,573       77,251       75,016  
Total operating expenses     35,860       33,824       140,726       133,672  
                                 
Operating income     20,089       16,481       78,868       66,491  
                                 
Financial and other expenses (income), net     (560 )     (1,097 )     1,750       941  
Taxes on income     3,624       4,276       14,251       12,619  
                                 
Net income     17,025       13,302       62,867       52,931  
                                 
Attributable to non-controlling interest     52       (65 )     423       336  
                                 
Net income attributable to Sapiens’ shareholders     16,973       13,367       62,444       52,595  
                                 
Basic earnings per share     0.30       0.24       1.13       0.95  
                                 
Diluted earnings per share     0.30       0.24       1.12       0.95  
                                 
Weighted average number of shares outstanding used to compute basic earnings per share (in thousands)     55,733       55,140       55,372       55,117  
                                 
Weighted average number of shares outstanding used to compute diluted earnings per share (in thousands)     55,910       55,521       55,721       55,570  

 

7


 

SAPIENS INTERNATIONAL CORPORATION N.V. AND SUBSIDIARIES

 

RECONCILIATION OF GAAP TO NON-GAAP RESULTS

U.S. dollars in thousands (except per share amounts)

 

    Three months ended     Year ended  
    December 31,     December 31,  
    2023     2022     2023     2022  
    (unaudited)     (unaudited)     (unaudited)     (unaudited)  
                         
GAAP revenue     130,859       119,463       514,584       474,736  
Valuation adjustment on acquired deferred revenue     55       23       220       92  
Non-GAAP revenue     130,914       119,486       514,804       474,828  
                                 
GAAP gross profit     55,949       50,305       219,594       200,163  
Revenue adjustment     55       23       220       92  
Amortization of capitalized software     1,501       1,517       5,775       5,840  
Amortization of other intangible assets     1,865       1,929       7,396       7,375  
Non-GAAP gross profit     59,370       53,774       232,985       213,470  
                                 
GAAP operating income     20,089       16,481       78,868       66,491  
Gross profit adjustments     3,421       3,469       13,391       13,307  
Capitalization of software development     (1,543 )     (1,238 )     (6,518 )     (6,097 )
Amortization of other intangible assets     1,169       1,115       4,403       4,783  
Stock-based compensation     698       759       3,658       3,960  
Acquisition-related costs (*)     318       472       339       1,033  
Non-GAAP operating income     24,152       21,058       94,141       83,477  
                                 
GAAP net income attributable to Sapiens’ shareholders     16,973       13,367       62,444       52,595  
Operating income adjustments     4,063       4,577       15,273       16,986  
Taxes on income     (955 )     78       (2,693 )     (2,411 )
Non-GAAP net income attributable to Sapiens’ shareholders     20,081       18,022       75,024       67,170  

 

(*) Acquisition-related costs pertain to charges on behalf of M&A agreements related to future performance targets and retention criteria, as well as third-party services, such as tax, accounting and legal rendered until the acquisition date.

 

8


 

Adjusted EBITDA Calculation
U.S. dollars in thousands

 

    Three months ended     Year ended  
    December 31,     December 31,  
    2023     2022     2023     2022  
                         
GAAP operating profit     20,089       16,481       78,868       66,491  
                                 
Non-GAAP adjustments:                                
Valuation adjustment on acquired deferred revenue     55       23       220       92  
Amortization of capitalized software     1,501       1,517       5,775       5,840  
Amortization of other intangible assets     3,034       3,044       11,799       12,158  
Capitalization of software development     (1,543 )     (1,238 )     (6,518 )     (6,097 )
Stock-based compensation     698       759       3,658       3,960  
Compensation related to acquisition and acquisition-related costs     318       472       339       1,033  
                                 
Non-GAAP operating profit     24,152       21,058       94,141       83,477  
                                 
Depreciation     1,115       1,034       3,865       4,242  
                                 
Adjusted EBITDA     25,267       22,092       98,006       87,719  

 

Summary of NON-GAAP Financial Information
U.S. dollars in thousands (except per share amounts)

 

    Q4 2023     Q3 2023     Q2 2023     Q1 2023     Q4 2022  
                               
Revenues     130,914       130,760       128,354       124,776       119,486  
Gross profit     59,370       59,260       57,992       56,363       53,774  
Operating income     24,152       24,058       23,417       22,514       21,058  
Adjusted EBITDA     25,267       24,777       24,393       23,569       22,092  
Net income to Sapiens’ shareholders     20,081       19,080       18,610       17,253       18,022  
                                         
Diluted earnings per share     0.36       0.34       0.33       0.31       0.32  

 

9


 

Non-GAAP Revenues by Geographic Breakdown
U.S. dollars in thousands

 

    Q4 2023     Q3 2023     Q2 2023     Q1 2023     Q4 2022  
                               
North America     54,882       54,848       52,116       50,371       50,801  
Europe     65,239       64,662       62,960       64,572       56,910  
Rest of the World     10,793       11,250       13,278       9,833       11,775  
                                         
Total     130,914       130,760       128,354       124,776       119,486  

 

Non-GAAP Revenue breakdown

U.S. dollars in thousands

 

    Three months ended     Year ended  
    December 31,     December 31,  
    2023     2022     2023     2022  
                         
Software products and re-occurring post-production services (*)     90,399       77,702       342,156       300,241  
Pre-production implementation services (**)     40,515       41,784       172,648       174,587  
                                 
Total Revenues     130,914       119,486       514,804       474,828  

 

    Three months ended     Year ended  
    December 31,     December 31,  
    2023     2022     2023     2022  
                         
Software products and re-occurring post-production services (*)     48,815       42,120       182,154       161,534  
Pre-production implementation services (**)     10,555       11,654       50,831       51,936  
                                 
Total Gross profit     59,370       53,774       232,985       213,470  

  

    Three months ended     Year ended  
    December 31,     December 31,  
    2023     2022     2023     2022  
                         
Software products and re-occurring post-production services (*)     54.0 %     54.2 %     53.2 %     53.8 %
Pre-production implementation services (**)     26.1 %     27.9 %     29.4 %     29.7 %
                                 
Gross Margin     45.4 %     45.0 %     45.3 %     45.0 %

 

(*) Software products and re-occurring post-production services include mainly subscription, term license, maintenance, application maintenance, cloud solutions and post-production services. This revenue stream is a mix of recurring and re-occurring in nature.

 

(**) Pre-production implementation services include mainly implementation services before go-live, which are one-time in nature.

 

10


 

Annual Recurring Revenue (“ARR”)

U.S. dollars in thousands

 

  Three months ended  
  December 31,  
  2023     2022  
    164,840       145,188  

  

Adjusted Free Cash-Flow
U.S. dollars in thousands

 

    Q4 2023     Q3 2023     Q2 2023     Q1 2023     Q4 2022  
                               
Cash-flow from operating activities     38,646       3,988       14,603       22,188       14,430  
Increase in capitalized software development costs     (1,543 )     (1,638 )     (1,679 )     (1,658 )     (1,238 )
Capital expenditures     (421 )     (696 )     (775 )     (634 )     (400 )
Free cash-flow     36,682       1,654       12,149       19,896       12,792  
                                         
Cash payments attributed to acquisition-related costs(*) (**)     221       -       -       30       1,100  
                                         
Adjusted free cash-flow     36,903       1,654       12,149       19,926       13,892  

 

(*) Included in cash-flow from operating activities

 

(**) Acquisition-related payments pertain to payments on behalf of M&A agreements related to future performance targets and retention criteria, as well as third-party services, such as, tax, accounting and legal rendered until the acquisition date.

 

11


 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED BALANCE SHEET

U.S. dollars in thousands

 

    December 31,     December 31,  
    2023     2022  
    (unaudited)     (unaudited)  
             
ASSETS            
             
CURRENT ASSETS            
Cash and cash equivalents     126,716       160,285  
Short-term bank deposit     75,400       20,000  
Trade receivables, net and unbilled receivables     90,273       93,382  
Other receivables and prepaid expenses     22,514       11,640  
Total current assets     314,903       285,307  
                 
LONG-TERM ASSETS                
Property and equipment, net     12,661       12,021  
Severance pay fund     3,605       3,996  
Goodwill and intangible assets, net     317,352       319,661  
Operating lease right-of-use assets     23,557       33,688  
Other long-term assets     17,546       13,671  
Total long-term assets     374,721       383,037  
                 
TOTAL ASSETS     689,624       668,344  
                 
LIABILITIES AND EQUITY                
                 
CURRENT LIABILITIES                
Trade payables     6,291       9,415  
Current maturities of Series B Debentures     19,796       19,796  
Accrued expenses and other liabilities     77,873       76,962  
Current maturities of operating lease liabilities     6,623       9,063  
Deferred revenue     38,541       30,720  
Total current liabilities     149,124       145,956  
                 
LONG-TERM LIABILITIES                
Series B Debentures, net of current maturities     39,543       59,275  
Deferred tax liabilities     10,820       11,363  
Other long-term liabilities     11,538       13,312  
Long-term operating lease liabilities     21,084       28,432  
Redeemable non-controlling interest     -       89  
Accrued severance pay     7,568       7,063  
Total long-term liabilities     90,553       119,534  
                 
EQUITY     449,947       402,854  
                 
TOTAL LIABILITIES AND EQUITY     689,624       668,344  

 

12


 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONSOLIDATED STATEMENT OF CASH FLOW
U.S. dollars in thousands

 

    For the Twelve months ended
December 31,
 
    2023     2022  
    (unaudited)     (unaudited)  
Cash flows from operating activities:            
Net income     62,867       52,931  
Reconciliation of net income to net cash provided by operating activities:                
Depreciation and amortization     21,439       22,240  
Accretion of discount on Series B Debentures     64       85  
Capital loss from sale of property and equipment     195       26  
Stock-based compensation related to options issued to employees     3,658       3,960  
                 
Net changes in operating assets and liabilities, net of amount acquired:                
Decrease (increase) in trade receivables, net and unbilled receivables     3,960       (21,860 )
Decrease in deferred tax liabilities, net     (3,003 )     (10,134 )
Decrease (increase) in other operating assets     (5,402 )     7,729  
Increase (decrease) in trade payables     (3,580 )     4,634  
Decrease in other operating liabilities     (8,948 )     (8,171 )
Increase (decrease) in deferred revenues     7,266       (7,738 )
Increase in accrued severance pay, net     909       78  
Net cash provided by operating activities     79,425       43,780  
                 
Cash flows from investing activities:                
                 
Purchase of property and equipment     (2,574 )     (2,757 )
Proceeds from (investments in) deposits     (55,499 )     26  
Proceeds from sale of property and equipment     48       54  
Payments for business acquisitions, net of cash acquired     (8,060 )     (3,466 )
Capitalized software development costs     (6,518 )     (6,097 )
Acquisition of intellectual property     (177 )     (200 )
Net cash used in investing activities     (72,780 )     (12,440 )
                 
Cash flows from financing activities:                
Proceeds from employee stock options exercised     4,809       -  
Distribution of dividend     (28,144 )     (38,579 )
Repayment of Series B Debenture     (19,796 )     (19,796 )
Acquisition of non-controlling interests     (161 )     -  
Dividend to non-controlling interest     (47 )     -  
Net cash used in financing activities     (43,339 )     (58,375 )
                 
Effect of exchange rate changes on cash and cash equivalents     3,125       (2,923 )
                 
Decrease in cash and cash equivalents     (33,569 )     (29,958 )
Cash and cash equivalents at the beginning of period     160,285       190,243  
                 
Cash and cash equivalents at the end of period     126,716       160,285  

 

13


  

Debentures Covenants

 

As of December 31, 2023, Sapiens was in compliance with all of its financial covenants under the indenture for the Series B Debentures, based on having achieved the following in its consolidated financial results:

 

Covenant 1

 

Target shareholders’ equity (excluding non-controlling interest): above $120 million.

 

Actual shareholders’ equity (excluding non-controlling interest) equal to $447.3 million.

 

Covenant 2

 

Target ratio of net financial indebtedness to net capitalization (in each case, as defined under the indenture for the Company’s Series B Debentures) below 65%.

 

Actual ratio of net financial indebtedness to net capitalization equal to (46.48)%.

 

Covenant 3

 

Target ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is below 5.5.

 

Actual ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is equal to (1.46).

 

14